Form 4 for TXG 10x Genomics, Inc.
Accepted 2023-11-16 00:00:00 ET · period of report 2023-11-14 · accession 0001610717-23-000358 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2023-11-16 | 2023-11-14 | TXG | Saxonov Serge | CEO, Dir | S - Sale | $39.52 | -2,000 | 854.9K | -0.2% | -$79.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2023-11-14 | S | D | 2,000 | $39.52 | 854,926 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $39.50 to $39.575. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |